1. Home
  2. News
  3. Argenica Therapeutics Ltd
  4. Interim Phase 1 Safety Report Confirms Safety of ARG-007
More Argenica Therapeutics Ltd news
Argenica Therapeutics LtdASX: AGN

Interim Phase 1 Safety Report Confirms Safety of ARG-007

Mar 5, 2023 at 9:36 PM EST · Issued by Argenica Therapeutics Ltd

Filed with ASX · Mar 5, 2023 at 9:36 PM EST · 5 pages · English

On 6ix: 6ix.com/news/interim-phase-1-safety-report-confirms-safety-of-arg-007

Argenica Therapeutics Ltd on 6ix

Story so far

  • Safety Review Committee Approves Third Cohort CommencementNov 18, 2022
  • Safety Review Committee Approves Second CohortNov 2, 2022
  • No Serious Safety Issues Observed in First CohortOct 26, 2022

Earlier from Argenica Therapeutics

  • Non-Dilutive Funding Received to Progress Alzheimers StudiesFeb 21, 2023
  • Preclinical Data Shows ARG007 Inhibits a Cause of AlzheimersFeb 8, 2023
  • Argenica Awarded $1.2m CRC-P Grant for TBI ProjectJan 19, 2023
  • Successful Completion of Phase 1 Clinical Trial DosingDec 20, 2022
  • SRC Approves Commencement Of Fourth And Final Cohort DosingDec 7, 2022

Later from Argenica Therapeutics

  • Significant Non-Dilutive Funding For Preclinical HIE StudiesMar 29, 2023
  • Latest Preclinical HIE Study ResultsApr 19, 2023
  • Final Phase1 Clinical Trial ReportMay 14, 2023
  • Argenica Successfully Completes $4.0m PlacementJun 1, 2023
  • ARG-007 Protects Brain Cells in Moderate TBI ModelJun 21, 2023
All Argenica Therapeutics news releases↗

Follow Argenica Therapeutics into a list and get an email when it puts out news.

Follow Argenica Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer